Population Pharmacokinetics of Prolonged Infusion Meropenem in Cystic Fibrosis (CF) Children

PHASE4CompletedINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

February 29, 2012

Primary Completion Date

January 31, 2014

Study Completion Date

January 31, 2014

Conditions
Cystic FibrosisPneumoniaPseudomonas Aeruginosa Infection
Interventions
DRUG

meropenem

meropenem 40mg/kg total body weight will be administered every 8 hours. Each infusion will be infused as a 3 hour infusion.

Trial Locations (7)

10032

Columbia University Medical Center Children's Hospital, New York

19134

St. Christopher's Hospital for Children, Philadelphia

27514

University of North Carolina, North Carolina Children's Hospital, Chapel Hill

43205

Nationwide Children's Hospital, Columbus

46202

Riley Hospital for Children, Indianapolis

75235

Children's Medical Center, Dallas

06106

Connecticut Children's Medical Center, Hartford

All Listed Sponsors
collaborator

Thrasher Research Fund

OTHER

lead

Joseph Kuti

OTHER

NCT01429259 - Population Pharmacokinetics of Prolonged Infusion Meropenem in Cystic Fibrosis (CF) Children | Biotech Hunter | Biotech Hunter